Review: Recent advances in the understanding of the pathophysiology of neuromyelitis optica spectrum disorder

被引:39
|
作者
Chang, V. T. W. [1 ]
Chang, H-M [2 ,3 ]
机构
[1] St Georges Univ London, London, England
[2] Univ British Columbia, Dept Obstet & Gynaecol, Vancouver, BC, Canada
[3] BC Childrens Hosp, Res Inst, Vancouver, BC, Canada
关键词
aquaporin; 4; astrocyte; autoimmune; myelin oligodendrocyte glycoprotein; neuromyelitis optica; neuromyelitis optica spectrum disorder; MYELIN-OLIGODENDROCYTE GLYCOPROTEIN; INSENSITIVE WATER CHANNEL; CENTRAL-NERVOUS-SYSTEM; MOG-ANTIBODY DISEASE; AQUAPORIN; DIAGNOSTIC-CRITERIA; MULTIPLE-SCLEROSIS; ORTHOGONAL ARRAYS; COMPLEMENT REGULATORS; MONOCLONAL-ANTIBODY;
D O I
10.1111/nan.12574
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Neuromyelitis optica is an autoimmune inflammatory disorder of the central nervous system that preferentially targets the spinal cord and optic nerve. Following the discovery of circulating antibodies against the astrocytic aquaporin 4 (AQP4) water channel protein, recent studies have expanded our knowledge of the unique complexities of the pathogenesis of neuromyelitis optica and its relationship with the immune response. This review describes and summarizes the recent advances in our understanding of the molecular mechanisms underlying neuromyelitis optica disease pathology and examines their potential as therapeutic targets. Additionally, we update the most recent research by proposing major unanswered questions regarding how peripheral AQP4 antibodies are produced and their entry into the central nervous system, the causes of AQP4-IgG-seronegative disease, why peripheral AQP4-expressing organs are spared from damage, and the impact of this disease on pregnancy.
引用
收藏
页码:199 / 218
页数:20
相关论文
共 50 条
  • [1] A comprehensive review of the advances in neuromyelitis optica spectrum disorder
    Siriratnam, Pakeeran
    Huda, Saif
    Butzkueven, Helmut
    van der Walt, Anneke
    Jokubaitis, Vilija
    Monif, Mastura
    [J]. AUTOIMMUNITY REVIEWS, 2023, 22 (12)
  • [2] Advances in the Treatment of Neuromyelitis Optica Spectrum Disorder
    Wallach, Asya Izraelit
    Tremblay, Matthew
    Kister, Ilya
    [J]. NEUROLOGIC CLINICS, 2021, 39 (01) : 35 - 49
  • [3] Recent Advances in Neuromyelitis Optica Spectrum Disorder: Pathogenesis, Mechanisms and Potential Treatments
    Du, Yi
    Li, Kaijun
    Liu, Wei
    Song, Ruitong
    Luo, Meifeng
    He, Jianfeng
    Xu, Xiaoyu
    Qu, Xiaosheng
    [J]. CURRENT PHARMACEUTICAL DESIGN, 2022, 28 (04) : 272 - 279
  • [4] Recent advances in the treatment of neuromyelitis optica spectrum disorders
    Romeo, Andrew R.
    [J]. CURRENT OPINION IN RHEUMATOLOGY, 2021, 33 (03) : 233 - 239
  • [5] Interleukin-6 in neuromyelitis optica spectrum disorder pathophysiology
    Fujihara, Kazuo
    Bennett, Jeffrey L.
    de Seze, Jerome
    Haramura, Masayuki
    Kleiter, Ingo
    Weinshenker, Brian G.
    Kang, Delene
    Mughal, Tabasum
    Yamamura, Takashi
    [J]. NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION, 2020, 7 (05):
  • [6] Satralizumab: A Review in Neuromyelitis Optica Spectrum Disorder
    Simon Fung
    Matt Shirley
    [J]. CNS Drugs, 2023, 37 : 363 - 370
  • [7] Satralizumab: A Review in Neuromyelitis Optica Spectrum Disorder
    Fung, Simon
    Shirley, Matt
    [J]. CNS DRUGS, 2023, 37 (04) : 363 - 370
  • [8] Inebilizumab: A Review in Neuromyelitis Optica Spectrum Disorder
    Tina Nie
    Hannah A. Blair
    [J]. CNS Drugs, 2022, 36 : 1133 - 1141
  • [9] Inebilizumab: A Review in Neuromyelitis Optica Spectrum Disorder
    Nie, Tina
    Blair, Hannah A.
    [J]. CNS DRUGS, 2022, 36 (10) : 1133 - 1141
  • [10] Neuromyelitis Optica Spectrum Disorder
    Wingerchuk, Dean M.
    Lucchinetti, Claudia F.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2022, 387 (07): : 631 - 639